Halozyme Therapeutics | HALO - Zysk Brutto Na Sprzedaży





Zysk Brutto Na Sprzedaży Zmiana Data
Acadia Pharmaceuticals USD 257.76M 778K 2025-12
Agios Pharmaceuticals USD 19.43M 1.34M 2026-03
Alnylam Pharmaceuticals USD 825M 4.3M 2026-03
Amarin USD 23.17M 961K 2025-12
Amgen USD 6.89B 415M 2025-12
Baxter International USD 891M 314M 2026-03
Cara Therapeutics USD 2.57M 1.11M 2025-03
Cytokinetics USD 19.2M 1.44M 2026-03
DBV Technologies USD 2.77M 33.21M 2025-09
Eli Lilly USD 15.92B 1.33B 2025-12
Esperion Therapeutics USD 140.59M 94.57M 2025-12
Halozyme Therapeutics USD 281.77M 2.41M 2025-09
Intrexon USD -297K 167K 2024-06
Ionis Pharmaceuticals USD 243M 48M 2026-03
MannKind USD 78.31M 76.21M 2025-12
Minerva Neurosciences -4.27M 26.79M 2024-12
Nektar Therapeutics USD 21.81M 8.06M 2025-12
Pfizer USD 11.04B 1.24B 2026-03
Rigel Pharmaceuticals USD 28.49M 7.01M 2024-06
United Therapeutics USD 315.5M 286.6M 2025-12
Vanda Pharmaceuticals USD 50.6M 5.5M 2024-12